Design Therapeutics (DSGN) Capital Expenditures (2020 - 2026)

Design Therapeutics has reported Capital Expenditures for 7 years, with the latest figure at $21000.0 in Q2 2026.

• Capital Expenditures for Q2 2026 came in at $21000.0, down 75.86% year-over-year; the trailing twelve-month figure through Jun 2026 was $55000.0 (down 61.54% YoY), and the FY2025 annual result was $193000.0, down 43.24% from the prior year.
• Capital Expenditures eased to $21000.0 in Q2 2026, from $34000.0 in the prior quarter.
• Over five years, Capital Expenditures peaked at $310000.0 in Q3 2022 and troughed at -$16000.0 in Q3 2024.
• A 5-year average of $115200.0 and a median of $87000.0 in 2023 frame the typical range for Capital Expenditures.
• The widest annual swing landed in 2022, when Capital Expenditures surged 130.3%; it then slumped 130.19% in 2024.
• A 5-year view of Capital Expenditures shows it stood at $288000.0 in 2022, then plunged by 90.62% to $27000.0 in 2023, then slumped by 159.26% to -$16000.0 in 2024, then soared by 312.5% to $34000.0 in 2025, then plunged by 38.24% to $21000.0 in 2026.
• Per Business Quant data, the three most recent Capital Expenditures figures were $21000.0 in Q2 2026, $34000.0 in Q4 2025, and $87000.0 in Q2 2025.